TIL Analysis
Oncology
Key Facts
About CellChorus
CellChorus is a private, early-stage biotech company founded in 2019 that has developed a unique AI-powered platform for dynamic single-cell functional analysis. Its core technology, TIMING™, visualizes and quantifies the behavior of thousands of individual cells in parallel, providing insights into cell therapy potency, antibody function, and immune response that are missed by conventional bulk or static single-cell methods. The company operates primarily as a technology platform and services provider, supporting pharmaceutical and biotech clients in preclinical research, candidate selection, and manufacturing consistency. CellChorus is positioned to address critical bottlenecks in immunotherapy development by delivering high-content, single-cell kinetic data.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |